Bobba Venkatadri, president and COO of ultrasound contrast vendor Molecular Biosystems, will add CEO to his list of titles. MBI's previous CEO and founder, Dr. Kenneth Widder, will remain chairman and continue to be responsible for strategic planning and
Bobba Venkatadri, president and COO of ultrasound contrast vendor Molecular Biosystems, will add CEO to his list of titles. MBI's previous CEO and founder, Dr. Kenneth Widder, will remain chairman and continue to be responsible for strategic planning and corporate development activities. Venkatadri's promotion culminated a succession plan agreed upon when he was hired in November 1995, according to the San Diego-based company.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.